177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001103
Abstract: OBJECTIVE Advanced pancreatic neuroendocrine tumors (pNETs) present a therapeutic challenge with targeted therapies like Everolimus and Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) showing beneficial effects in various cohort studies and randomized trials. Currently there is… read more here.
Keywords: dotatate; therapy; meta analysis; everolimus advanced ... See more keywords
Use of everolimus in advanced hormone receptor–positive metastatic breast cancer in a multicenter national observational study.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e12548
Abstract: e12548Background: The everolimus-exemestane combination has been included in the International guidelines for advanced HR+ breast cancer (mBC) since the results of the Bolero-2 trial. Marketing authorization has been granted in France in July 2012 and… read more here.
Keywords: use everolimus; use; everolimus advanced; breast cancer ... See more keywords